Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study

Simona Di Giambenedetto, V Spagnuolo, L Galli, A Bigoloni, S Nozza, Ad Monforte, A Antinori, A Di Biagio, S Rusconi, G Guaraldi, A Lazzarin, A. Castagna

Risultato della ricerca: Contributo in rivistaContributo a convegnopeer review

Abstract

The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis.
Lingua originaleEnglish
pagine (da-a)19806-19806
Numero di pagine1
RivistaJournal of the International AIDS Society
Volume17
DOI
Stato di pubblicazionePubblicato - 2014
EventoHIV Drug Therapy Glasgow Congress 2014 - Glasgow
Durata: 2 nov 20146 nov 2014

Keywords

  • Atazanavir
  • HIV
  • monotherapy

Fingerprint Entra nei temi di ricerca di 'Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study'. Insieme formano una fingerprint unica.

Cita questo